Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · HIV/AIDS

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Bae: AZT/3TC/NVP vs AZT/3TC/NVP

Maternal Grade 3/4 Severe Adverse Events · HIV‐1 Infected Pregnant Women Who Have CD4>200 Compared with Those Who Have CD4<200 Cells/mm3

It is very uncertain whether phanuphak: AZT/3TC/NVP (PMTCT) changes maternal Grade 3/4 Severe Adverse Events compared with AZT/3TC/NVP (ART) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.98 [0.65, 6.03]
1 study · 244 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Maternal Grade 3/4 Severe Adverse Events · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes maternal Grade 3/4 Severe Adverse Events compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.09 [0.77, 1.53]
1 study · 824 participants
Very low